DaVita Inc., formerly Total Renal Care Holdings, Inc.
Quarterly financial highlights include: -- Continental U.S. dialysis revenue per treatment (excluding lab, management fees and other revenue) in the third quarter was $260.41 as compared to $249.23 in the second quarter, or a 4.5% increase. Continental U.S. DSO at quarter end was 77 days, including Florida Medicare laboratory receivables. This represents a 3-day improvement from the second quarter. -- The continental U.S. EBITDA margin for the third quarter was 21.4%. Net cash provided by operations for the three and nine months ended September 30, 2000 was $84 million and $195 million, respectively. -- As of the date of this release our leverage ratio (the ratio of net debt to EBITDA) is 3.2x, down from 5.5x at the beginning of the year. Total continental U.S. treatments for the third quarter were 1,347,970. Non-acquired treatment growth was 5.7%, which included same center treatment growth of 4.8%. -- At September 30, 2000 we operated 487 outpatient centers in the continental U.S. serving over 41,000 patients. During the quarter we sold 1 center and closed 1 under-performing center. Included in our continental patient and facility count are 4,700 patients in 55 centers under management. We also provide acute hemodialysis services to inpatients at approximately 290 hospitals.
Kent Thiry, Chairman and CEO stated, "The DaVita team worked hard to meet, and in several cases exceed, the expectations of each of our stakeholders. Although we still have a material number of poor contracts and an extensive need to build fundamental infrastructure, our team is relentlessly pursuing operational excellence."
Specifics of the third quarter charges and other developments: -- As a result of the restructuring of our revolving and term loan credit facilities in July 2000, we wrote-off certain financing costs reflected in the third quarter financial statements as a $3.5 million extraordinary loss, net of tax, and additional debt expense of $1.2 million pre-tax, or $0.01 per share after-tax. -- In the third quarter we have ceased recognizing Medicare revenue from services provided at our Florida laboratory. This policy does not reflect a change in our determination that the tests performed are medically justified and should ultimately be reimbursed. Our decision is based solely on the fact that we have not been paid for services rendered in over two years and we are uncertain when we will achieve resolution of this matter. -- In October the United States District Court entered a Final Judgment approving the Stipulation of Settlement that DaVita previously entered into with the plaintiffs in the consolidated securities class actions that were filed against Total Renal Care and several of its former officers in February 1999. As a result of the Final Judgment, the class actions are dismissed and the litigation is over. DaVita's portion of the settlement was funded and recorded in the second quarter of 2000.
This release contains forward-looking statements regarding the Company's expected third quarter results and ability to sustain those results. Actual results could differ materially from these forward-looking statements. Factors which could cause or contribute to such differences include the uncertainties associated with governmental regulation, general economic and other market conditions, and the "risk factors" set forth in the Company's SEC filings, including its Form 10-Q for the quarter ended June 30, 2000. These risks include (1) possible changes in private and government reimbursement rates, (2) the concentration of profits generated from private indemnity patients, (3) the ongoing payment suspension and review of the Company's Florida laboratory subsidiary by its Medicare carrier and the Department of Justice, (4) its ability to maintain contracts with physician medical directors and (5) the risks relating to the large amount and terms of the Company's outstanding debt. The forward-looking statements should be considered in light of these risks and uncertainties.
DAVITA INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
Three months ended Nine months ended
September 30, September 30,
2000 1999 2000 1999
Net operating revenues $362,535 $367,168 $1,113,556 $1,072,231
Operating expenses
Dialysis and lab facilities 248,734 250,433 775,746 730,621
General and administrative 29,920 32,725 93,460 85,892
Depreciation and
amortization 26,927 28,956 84,315 82,104
Provision for uncollectible
accounts 7,048 17,002 32,555 63,187
Impairments and valuation
adjustments 2,945 4,414 19,545
Total operating expenses 312,629 332,061 990,490 981,349
Operating income 49,906 35,107 123,066 90,882
Other income (loss) 1,418 1,241 (9,171) 4,505
Debt expense 26,370 30,184 94,017 78,391
Minority interests in income
of consolidated subsidiaries (1,147) (1,586) (3,168) (6,425)
Income before income taxes 23,807 4,578 16,710 10,571
Income tax expense 10,657 2,319 15,068 7,163
Income before extraordinary
item 13,150 2,259 1,642 3,408
Extraordinary loss related
to early extinguishment of
debt, net of tax of $2,222 3,490 3,490
Net income (loss) $ 9,660 $2,259 $(1,848) $3,408
Earnings (loss)
per common share:
Income before
extraordinary item $0.16 $0.03 $0.02 $0.04
Extraordinary loss,
net of tax (0.04) (0.04)
Net income (loss) $0.12 $0.03 $(0.02) $0.04
Earnings (loss) per common
share-assuming dilution:
Income before
extraordinary item $0.16 $0.03 $0.02 $0.04
Extraordinary loss,
net of tax (0.04) (0.04)
Net income (loss) $0.12 $0.03 $(0.02) $0.04
Supplemental Information:
Earnings pre common share
- assuming dilution and
excluding the financing
costs write-off $0.17
DAVITA INC.
CONSOLIDATED BALANCE SHEETS
(in thousands except per share data)
September 30, December 31,
2000 1999
ASSETS
Cash and cash equivalents $38,574 $107,981
Accounts receivable 302,640 390,329
Inventories 37,425 32,916
Other current assets 17,090 32,082
Income tax receivable 45,645
Deferred income taxes 53,433 45,795
Total current assets 449,162 654,748
Property and equipment, net 241,381 285,449
Intangible assets, net 940,083 1,069,672
Investments in third-party
dialysis businesses 32,988 35,552
Deferred income taxes 5,495 6,553
Other long-term assets 2,174 4,744
$1,671,283 $2,056,718
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable $69,488 $121,561
Accrued compensation and benefits 64,465 47,647
Other liabilities 97,024 77,141
Current portion of long-term debt 48,907 26,585
Income taxes payable 5,320
Long-term debt potentially callable
under covenant provisions 1,425,610
Total current liabilities 285,204 1,698,544
Long-term debt, less $0 and $1,425,610
potentially callable classified as current 1,033,635 5,696
Other long-term liabilities 4,960 3,497
Minority interests 16,801 22,577
Shareholders' equity
Preferred stock ($0.001 par value;
5,000,000 shares authorized; none
issued or outstanding)
Common stock ($0.001 par value,
195,000,000 shares authorized;
81,722,612 and 81,193,011 shares
issued and outstanding) 82 81
Additional paid-in capital 427,404 426,025
Notes receivable from shareholders (163) (192)
Accumulated other comprehensive loss (4,718)
Accumulated deficit (96,640) (94,792)
Total shareholders' equity 330,683 326,404
$1,671,283 $2,056,718
SOURCE: DaVita Inc
Contact: LeAnne Zumwalt, Investor Relations of DaVita Inc.,
310-750-2072
Website: http://www.davita.com/